Analyst Ratings for Royalty Pharma (RPRX)
RPRX Rating Summary
RPRX Price Target Summary
- Highest: $61.00 (Morgan Stanley)
- Lowest: $49.00 (UBS)
- Average: $52.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$52.50 (+15.6%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 80%
Avg. $ Target:
$52.50 (+15.6%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 80%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/30/2026 | UBS | Ashwani Verma | Upgrade | Buy (Neutral) |
49.00 (38.00) |
40.41 (45.41) |
12.37% | Details |
| 9/30/2025 | Goldman Sachs » Updated 2/13/2026 |
Asad Haider | New Coverage | Buy (N/A) |
51.00 (45.00) |
35.25 (45.41) |
28.82% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
